Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease

…, D Le Febvre de Nailly, F Charbonnier-Beaupel… - Cell and tissue …, 2018 - Springer
There is currently no cure for Parkinson’s disease. The symptomatic therapeutic strategy
essentially relies on dopamine replacement whose efficacy was demonstrated more than 50 …

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: A randomized crossover clinical trial

…, C Bonnet, F CharbonnierBeaupel… - Annals of …, 2011 - Wiley Online Library
… 12,5 = 53.3, p = 0.0002 for the effect of entacapone in the COMT HH group; F 12,4 = 10.5, p
= 0.02 for the effect of entacapone in the COMT LL group; F 1,31 = 4.5, p = 0.04 for genotype/…

[PDF][PDF] RAD51 haploinsufficiency causes congenital mirror movements in humans

…, S Groppa, S Klebe, F Charbonnier-Beaupel… - The American Journal of …, 2012 - cell.com
Congenital mirror movements (CMM) are characterized by involuntary movements of one
side of the body that mirror intentional movements on the opposite side. CMM reflect …

The autophagy/lysosome pathway is impaired in SCA7 patients and SCA7 knock-in mice

…, MP Muriel, F Beaumatin, F Charbonnier-Beaupel… - Acta …, 2014 - Springer
There is still no treatment for polyglutamine disorders, but clearance of mutant proteins might
represent a potential therapeutic strategy. Autophagy, the major pathway for organelle and …

A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia

…, M Vidailhet, N Cozic, F Charbonnier-Beaupel… - Neurology, 2016 - AAN Enterprises
Objective: To evaluate the efficacy and safety of zonisamide in patients with myoclonus-dystonia.
Methods: We conducted a randomized, double-blind, placebo-controlled crossover trial …

Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease

…, K Tahiri, F Charbonnier-Beaupel… - Parkinsonism & related …, 2014 - Elsevier
… b , Stéphanie Lejeune a c , Florence Cormier-Dequaire a c , Khadija Tahiri c , Fanny
Charbonnier-Beaupel c d e , Nathalie Rouaix f , Alain Duhamel … Fanny Charbonnier-Beaupel: 1c …

[HTML][HTML] Bee venom for the treatment of Parkinson disease–a randomized controlled clinical trial

…, N Abuaf, H Gaouar, S Salhi, F Charbonnier-Beaupel… - PloS one, 2016 - journals.plos.org
In the present study, we examined the potential symptomatic and/or disease-modifying effects
of monthly bee venom injections compared to placebo in moderatly affected Parkinson …

Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinesia

F Charbonnier-Beaupel, M Malerbi… - Journal of …, 2015 - Soc Neuroscience
In Parkinson's disease, long-term dopamine replacement therapy is complicated by the
appearance of l-DOPA-induced dyskinesia (LID). One major hypothesis is that LID results from …

A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing–remitting multiple sclerosis

…, E Maillart, A Ungureanu, F Charbonnier-Beaupel… - Journal of …, 2023 - Springer
Background Multiple sclerosis (MS) is associated with regulatory T cells (Tregs) insufficiency
while low-dose interleukin-2 (IL2 LD ) activates Tregs and reduces disease activity in …

Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease

…, M Vidailhet, F CharbonnierBeaupel… - Movement …, 2018 - Wiley Online Library
Background Impulse control disorders are frequently associated with dopaminergic therapy
in Parkinson's disease. Genetic studies have suggested a high heritability of impulse control …